Back to companies

Sarepta Therapeutics Inc: Overview

Sarepta Therapeutics Inc (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-5051, SRP-9001, SRP-9003 and SRP-5045 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.

Headquarters United States of America

Address 215 1st St Ste 415, Cambridge, Massachusetts, 02142-1213


Telephone 1 617 2744000

No of Employees 840

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange SRPT (NASD)

Revenue (2020) $701.9M 30% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX 24.4% (2020 vs 2019)

Market Cap* $9.7B

Net Profit Margin (2020) XXX 41.9% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Sarepta Therapeutics Inc

90+

Pipeline Drugs

Identify which of Sarepta Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

60+

Clinical Trials

Determine Sarepta Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

60+

Catalyst Calendar

Proactively evaluate Sarepta Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Sarepta Therapeutics Inc’s relevant decision makers and contact details.

40+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Sarepta Therapeutics Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

9

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Marketed Drugs

Understand Sarepta Therapeutics Inc’s commercialized product portfolio to stay one step ahead of the market.

100+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Sarepta Therapeutics Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Amondys 45 - Duchenne Muscular Dystrophy EXONDYS
Exondys 51 - Duchenne Muscular Dystrophy VYONDYS
Vyondys 53 - Duchenne Muscular Dystrophy AMONDYS
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In August, the company entered into a license agreement with the Broad Institute of MIT and Harvard for MyoAAV in Duchenne muscular dystrophy and certain other neuromuscular and cardiac indications.
2022 Others In June, the company announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on SRP-5051 (vesleteplirsen) to treat patients with Duchenne muscular dystrophy.
2022 Contracts/Agreements In February, the company entered a research partnership and option agreement with GenEdit to develop gene-editing therapies for neuromuscular diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Sarepta Therapeutics Inc Pfizer Inc Sanofi Daiichi Sankyo Co Ltd Nippon Shinyaku Co Ltd
Headquarters United States of America United States of America France Japan Japan
City Cambridge New York Paris Chuo-Ku Kyoto-Shi
State/Province Massachusetts New York - Tokyo Kyoto
No. of Employees 840 79,000 95,442 16,458 2,059
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Douglas S. Ingram Director; Chief Executive Officer; President Executive Board 2017 59
M. Kathleen Behrens, Ph.D. Chairwoman Executive Board 2015 69
Ian M. Estepan Executive Vice President; Chief Financial Officer Senior Management 2020 46
Alison Nasisi Chief People Officer Senior Management 2021 -
Louise Rodino-Klapac, Ph.D Chief Scientific Officer; Head - Research and Development Senior Management 2021 44
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer